[go: up one dir, main page]

CL2019003093A1 - Anticuerpos anti-trem2 y métodos para utilizarlos. - Google Patents

Anticuerpos anti-trem2 y métodos para utilizarlos.

Info

Publication number
CL2019003093A1
CL2019003093A1 CL2019003093A CL2019003093A CL2019003093A1 CL 2019003093 A1 CL2019003093 A1 CL 2019003093A1 CL 2019003093 A CL2019003093 A CL 2019003093A CL 2019003093 A CL2019003093 A CL 2019003093A CL 2019003093 A1 CL2019003093 A1 CL 2019003093A1
Authority
CL
Chile
Prior art keywords
methods
trem2 antibodies
compositions
antibodies
trem2
Prior art date
Application number
CL2019003093A
Other languages
English (en)
Inventor
Eric Brown
Tina Schwabe
Philip Kong
Ilaria Tassi
Seung-Joo Lee
Arnon Rosenthal
Robert Pejchal
Nels P Nielson
Original Assignee
Alector Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alector Llc filed Critical Alector Llc
Publication of CL2019003093A1 publication Critical patent/CL2019003093A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA PRESENTE DESCRIPCIÓN SE DIRIGE, EN LÍNEAS GENERALES, A COMPOSICIONES QUE INCLUYEN ANTICUERPOS, POR EJEMPLO, ANTICUERPOS MONOCLONALES, FRAGMENTOS DE ANTICUERPOS, ETC., QUE SE UNEN ESPECÍFICAMENTE A UNA PROTEÍNA TREM2, POR EJEMPLO, UNA TREM2 DE MAMÍFERO O TREM2 HUMANA, Y EL USO DE ESTAS COMPOSICIONES PARA PREVENIR, REDUCIR EL RIESGO O TRATAR A UN INDIVIDUO QUE LO NECESITE.
CL2019003093A 2017-08-03 2019-10-28 Anticuerpos anti-trem2 y métodos para utilizarlos. CL2019003093A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762541019P 2017-08-03 2017-08-03
US201862636095P 2018-02-27 2018-02-27

Publications (1)

Publication Number Publication Date
CL2019003093A1 true CL2019003093A1 (es) 2020-03-20

Family

ID=63364160

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019003093A CL2019003093A1 (es) 2017-08-03 2019-10-28 Anticuerpos anti-trem2 y métodos para utilizarlos.
CL2020001974A CL2020001974A1 (es) 2017-08-03 2020-07-28 Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2020001974A CL2020001974A1 (es) 2017-08-03 2020-07-28 Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)

Country Status (34)

Country Link
US (3) US10676525B2 (es)
EP (2) EP3601358B1 (es)
JP (3) JP2020533948A (es)
KR (2) KR20250026882A (es)
CN (3) CN119192376A (es)
AU (1) AU2018311055B2 (es)
BR (1) BR112019022752A2 (es)
CA (1) CA3061755A1 (es)
CL (2) CL2019003093A1 (es)
CO (1) CO2019012210A2 (es)
CR (3) CR20230170A (es)
DK (1) DK3601358T5 (es)
EC (1) ECSP19078429A (es)
ES (1) ES2952982T3 (es)
FI (1) FI3601358T3 (es)
HR (1) HRP20230675T1 (es)
HU (1) HUE062436T2 (es)
IL (2) IL270235B2 (es)
LT (1) LT3601358T (es)
MD (1) MD3601358T2 (es)
MX (2) MX2019012868A (es)
MY (1) MY201526A (es)
NZ (1) NZ758301A (es)
PE (1) PE20200148A1 (es)
PH (1) PH12019502459A1 (es)
PL (1) PL3601358T3 (es)
PT (1) PT3601358T (es)
RS (1) RS64419B1 (es)
SI (1) SI3601358T1 (es)
SM (1) SMT202300281T1 (es)
TW (3) TWI811229B (es)
UA (1) UA129513C2 (es)
WO (1) WO2019028292A1 (es)
ZA (2) ZA201906730B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2955086A1 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
MX388410B (es) 2014-09-28 2025-03-20 Univ California Modulacion de celulas mieloides estimulantes y no estimulantes.
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
MX2019012868A (es) 2017-08-03 2019-11-28 Alector Llc Anticuerpos anti-trem2 y metodos para utilizarlos.
BR112020011833A2 (pt) 2017-12-12 2020-11-24 Pionyr Immunotherapeutics, Inc. anticorpos anti-trem2 e métodos relacionados
JP7607559B2 (ja) 2018-11-26 2024-12-27 デナリ セラピューティクス インコーポレイテッド 脂質代謝調節不全の治療方法
EA202192294A1 (ru) * 2019-02-20 2021-12-24 Денали Терапьютикс Инк. Антитела к trem2 и способы их применения
WO2021101823A1 (en) * 2019-11-22 2021-05-27 Eli Lilly And Company Trem2 antibodies and uses thereof
JP2023505279A (ja) * 2019-12-05 2023-02-08 アレクトル エルエルシー 抗ｔｒｅｍ２抗体の使用方法
WO2021146256A1 (en) 2020-01-13 2021-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
AU2021208482B2 (en) 2020-01-13 2025-12-11 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
WO2021173565A1 (en) 2020-02-24 2021-09-02 Alector Llc Methods of use of anti-trem2 antibodies
EP4126953A2 (en) * 2020-04-03 2023-02-08 Alector LLC Methods of use of anti-trem2 antibodies
EP4337317A1 (en) 2021-05-14 2024-03-20 Genentech, Inc. Agonists of trem2
EP4448563A1 (en) 2021-12-17 2024-10-23 Denali Therapeutics Inc. Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptides
KR20240149428A (ko) 2022-02-23 2024-10-14 알렉터 엘엘씨 항-trem2 항체의 사용 방법
WO2023192282A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
US20250215077A1 (en) 2022-03-28 2025-07-03 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
JP2025529287A (ja) 2022-09-06 2025-09-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル マルファン症候群の処置のためのｔｒｅｍ－２アゴニスト
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2024253420A1 (ko) * 2023-06-09 2024-12-12 재단법인대구경북과학기술원 인간 trem2 단백질에 특이적으로 결합하는 인간 항체 및 이의 용도
TW202515919A (zh) 2023-09-01 2025-04-16 比利時商艾托斯比利時公司 抗ｔｒｅｍ２抗體及使用方法
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025166058A1 (en) * 2024-01-31 2025-08-07 Alector Llc Multi-specific proteins that bind to trem2 and transferrin receptor and uses therefor
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
CN118420764A (zh) * 2024-04-02 2024-08-02 上海宏成药业有限公司 抗trem2抗体及其用途
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
DK187280A (da) 1980-04-30 1981-10-31 Novo Industri As Ruhedsreducerende middel til et fuldvaskemiddel fuldvaskemiddel og fuldvaskemetode
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
ATE295420T1 (de) 1992-02-06 2005-05-15 Chiron Corp Marker für krebs und biosynthetisches bindeprotein dafür
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
JP2002514895A (ja) 1995-09-28 2002-05-21 アレクション、ファーマスーティカルズ、インコーポレーテッド ブタ細胞相互作用タンパク質
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP2002519030A (ja) 1998-06-26 2002-07-02 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒトシグナルペプチド含有タンパク質
ATE303445T1 (de) 1999-10-04 2005-09-15 Medicago Inc Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6849425B1 (en) * 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
US20090081199A1 (en) 2001-03-20 2009-03-26 Bioxell S.P.A. Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
CA2342376C (en) 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
EP2072059A1 (en) 2001-10-12 2009-06-24 Schering Corporation Use of bispecific antibodies to regulate immune responses
JP2004073182A (ja) 2002-05-24 2004-03-11 Takeda Chem Ind Ltd インスリン抵抗性改善剤
WO2003099331A1 (fr) 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited Agents renforçateurs de la résistance à l'insuline
CA2502413A1 (en) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
WO2004041170A2 (en) 2002-11-01 2004-05-21 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP4902961B2 (ja) 2002-12-23 2012-03-21 シェーリング コーポレイション 哺乳動物サイトカインの用途；関連試薬
WO2004074506A2 (en) 2003-02-13 2004-09-02 Mergen Ltd Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
WO2006073941A2 (en) 2004-12-31 2006-07-13 Genentech, Inc. Polypeptides that bind br3 and uses thereof
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
US8101345B1 (en) 2005-03-25 2012-01-24 Isis Pharmaceuticals, Inc. Proinflammatory nucleic acids
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP4316465A3 (en) 2006-03-15 2024-04-24 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
DE202006007499U1 (de) 2006-05-11 2007-01-11 Osaka University Verwendung einer Zusammensetzung, die Plexin-A1-DAP12-Interaktion inhibiert, zur Behandlung von Entzündungs-, Autoimmun- oder Knochenresorptionserkrankungen
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
WO2008042261A2 (en) * 2006-09-28 2008-04-10 Elusys Therapeutics, Inc. Anti-anthrax antibody, formulations thereof, and methods of use
US7673853B2 (en) 2006-10-12 2010-03-09 Cordell Eldred Ebeling Fencing section with adjustable fencing members
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
CA2675583A1 (en) * 2007-01-16 2008-07-24 Wyeth Inflammation treatment, detection and monitoring via trem-1
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
AU2008298603B2 (en) 2007-09-14 2015-04-30 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
JP2010540660A (ja) 2007-10-05 2010-12-24 ユニバーシティ オブ メリーランド，ボルチモア 哺乳類内の赤血球生成を刺激する新規の組成物および方法
KR100960684B1 (ko) 2008-02-22 2010-05-31 전남대학교산학협력단 Ｇａ733-2 발현 억제제로서의 ｔｒｅｍ-2 유전자, 및 이를포함하는 형질전환 동물 및 이의 사용방법
EP2186928A1 (en) 2008-11-14 2010-05-19 Enthone, Inc. Method for the post-treatment of metal layers
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
US8513185B2 (en) 2009-10-13 2013-08-20 Alexander B. Sigalov Inhibition of TREM receptor signaling with peptide variants
WO2011069104A2 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
TWI653333B (zh) * 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
CA2805875C (en) 2010-07-16 2021-08-24 Adimab, Llc Libraries comprising segmental pools, and methods for their preparation and use
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
EP2654792A4 (en) 2010-12-22 2016-05-11 Abbvie Inc HALF IMMUNOGLOBULIN BINDING PROTEINS AND USES THEREOF
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
TWI559929B (en) * 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
WO2014074942A1 (en) 2012-11-08 2014-05-15 Illumina, Inc. Risk variants of alzheimer's disease
CA2825821A1 (en) 2013-08-28 2015-02-28 Chiesi Farmaceutici S.P.A. 1-phenylalkanecarboxylic acid derivatives for the treatment of alzheimer's disease and multiple sclerosis
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
US20170218091A1 (en) 2014-07-03 2017-08-03 Abbvie Inc. Monovalent binding proteins
CA2955086A1 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
MX388410B (es) * 2014-09-28 2025-03-20 Univ California Modulacion de celulas mieloides estimulantes y no estimulantes.
US20170334977A1 (en) * 2014-10-20 2017-11-23 The Brigham And Women's Hospital, Inc. Targeting Apolipoprotein E (APOE) in Neurologic Disease
MX2017012805A (es) 2015-04-07 2018-04-11 Genentech Inc Complejo de unión a antígenos con actividad agonista y métodos de uso.
JP2018516901A (ja) 2015-05-18 2018-06-28 シナプテック・ディヴェロップメント・エルエルシーＳｙｎａｐｔｅｃ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｌｃ アミロイドβのガランタミンクリアランス
US20180194861A1 (en) 2015-07-10 2018-07-12 Abbvie Inc. IgM- or IgE-Modified Binding Proteins and Uses Thereof
WO2017058866A1 (en) 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
JP7725185B2 (ja) * 2015-10-06 2025-08-19 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法
KR102415925B1 (ko) * 2016-01-11 2022-07-04 삼성디스플레이 주식회사 표시장치
US11066456B2 (en) 2016-02-25 2021-07-20 Washington University Compositions comprising TREM2 and methods of use thereof
WO2018015573A2 (en) 2016-07-22 2018-01-25 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Trem2 cleavage modulators and uses thereof
SG11201900744SA (en) 2016-08-12 2019-02-27 Janssen Biotech Inc Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
EP3570883A2 (en) 2017-01-17 2019-11-27 Yeda Research and Development Co. Ltd Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
US20190336615A1 (en) 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
US20190008812A1 (en) 2017-07-07 2019-01-10 Washington University Methods for treating microglial dysfunction
WO2019021233A1 (en) 2017-07-27 2019-01-31 Novartis Ag TREM2 VARIANTS RESISTANT TO SHEDDASE
MX2019012868A (es) 2017-08-03 2019-11-28 Alector Llc Anticuerpos anti-trem2 y metodos para utilizarlos.
CR20190486A (es) 2017-08-03 2020-02-10 Alector Llc Anti-cd33 antibodies and methods of use thereof
CN111448212A (zh) 2017-09-14 2020-07-24 戴纳立制药公司 抗trem2抗体及其使用方法
US11993790B2 (en) 2017-10-03 2024-05-28 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
WO2019079529A1 (en) 2017-10-17 2019-04-25 The Translational Genomics Research Institute TREM2 AGONISTS FOR STIMULATING MICROGLIA AND IDENTIFICATION METHODS
BR112020011833A2 (pt) 2017-12-12 2020-11-24 Pionyr Immunotherapeutics, Inc. anticorpos anti-trem2 e métodos relacionados
JP2021513969A (ja) 2018-02-14 2021-06-03 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ Ｔｒｅｍまたはｔｒｅｍｌタンパク質を調節するための組成物および使用方法
EP4126953A2 (en) * 2020-04-03 2023-02-08 Alector LLC Methods of use of anti-trem2 antibodies
EP4337317A1 (en) * 2021-05-14 2024-03-20 Genentech, Inc. Agonists of trem2

Also Published As

Publication number Publication date
JP2024147536A (ja) 2024-10-16
MY201526A (en) 2024-02-27
EP4248996A3 (en) 2023-11-08
US11634489B2 (en) 2023-04-25
EP4248996A2 (en) 2023-09-27
UA129513C2 (uk) 2025-05-21
JP2020533948A (ja) 2020-11-26
ECSP19078429A (es) 2020-02-28
CO2019012210A2 (es) 2020-04-01
CA3061755A1 (en) 2019-02-07
TW201912654A (zh) 2019-04-01
DK3601358T5 (da) 2024-09-02
ES2952982T3 (es) 2023-11-07
CN119192376A (zh) 2024-12-27
KR20250026882A (ko) 2025-02-25
PE20200148A1 (es) 2020-01-17
MD3601358T2 (ro) 2023-10-31
RS64419B1 (sr) 2023-09-29
JP7554247B2 (ja) 2024-09-19
CR20230170A (es) 2023-05-31
IL270235A (es) 2019-12-31
AU2018311055B2 (en) 2025-05-29
PT3601358T (pt) 2023-08-30
AU2018311055A1 (en) 2019-11-14
US20230312712A1 (en) 2023-10-05
HRP20230675T1 (hr) 2023-09-29
SMT202300281T1 (it) 2023-11-13
TW202342547A (zh) 2023-11-01
ZA201906730B (en) 2023-04-26
IL270235B1 (en) 2024-10-01
CN119192377A (zh) 2024-12-27
IL315241A (en) 2024-10-01
KR20200033794A (ko) 2020-03-30
CL2020001974A1 (es) 2020-10-23
WO2019028292A1 (en) 2019-02-07
KR102769231B1 (ko) 2025-02-20
CR20230169A (es) 2023-05-31
FI3601358T3 (fi) 2023-07-20
CN110621696A (zh) 2019-12-27
LT3601358T (lt) 2023-08-10
EP3601358B1 (en) 2023-05-17
JP2023029882A (ja) 2023-03-07
HUE062436T2 (hu) 2023-11-28
US10676525B2 (en) 2020-06-09
PH12019502459A1 (en) 2020-07-20
MX2019012868A (es) 2019-11-28
MX2024001803A (es) 2024-03-06
TW202511296A (zh) 2025-03-16
BR112019022752A2 (pt) 2020-05-19
PL3601358T3 (pl) 2023-10-02
NZ758301A (en) 2023-07-28
IL270235B2 (en) 2025-02-01
SI3601358T1 (sl) 2023-10-30
EP3601358A1 (en) 2020-02-05
CR20190485A (es) 2020-02-10
TWI811229B (zh) 2023-08-11
ZA202211057B (en) 2024-02-28
US20190040130A1 (en) 2019-02-07
CN110621696B (zh) 2024-10-25
US20200317776A1 (en) 2020-10-08
TWI868807B (zh) 2025-01-01
DK3601358T3 (da) 2023-07-31

Similar Documents

Publication Publication Date Title
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
CL2019003095A1 (es) Anticuerpos anti-cd33 y métodos para utilizarlos.
MX2017012802A (es) Anticuerpos antisortilina y métodos para su uso.
ECSP20082648A (es) Anticuerpos anti-sirpa y métodos de utilización de los mismos
CL2018002998A1 (es) Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4
MX2019011927A (es) Anticuerpos anti-ilt4 y fragmentos de union a antigeno.
CL2018000744A1 (es) Anticuerpos anti-tigit (inmunoreceptor de linfocitos t con dominios ig e itim) y metodos de uso.
MX2020004027A (es) Anticuerpos especificos cd47/pd-l1.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
MX2021002299A (es) Anticuerpos de anti-cd33 y metodos para usarlos.
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CR20180065A (es) Constructos de anticuerpo biespecíficos que se unen a egfrviii y cd3
MX2018003410A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
MX2017001531A (es) Anticuerpos anti-trem2 y metodos de uso de los mismos.
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
MX2020013172A (es) Anticuerpos anti-siglec-7 y sus metodos de uso.
CL2021002866A1 (es) Tratamiento de la cefalea usando anticuerpos anti-cgrp.
AR112401A1 (es) Anticuerpos anti-cd33 y métodos para utilizarlos
AR115992A2 (es) Proteínas de unión a antígeno que activan el receptor de leptina